The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of immunohistochemical evaluation of DNA repair proteins to demonstrate cisplatin response prediction in resected NSCLC squamous cell carcinoma.
W. E. Pierceall
Stock Ownership - On-Q-ity
Research Funding - On-Q-ity
K. M. Sprott
Stock Ownership - On-Q-ity
Research Funding - On-Q-ity
E. Brambilla
No relevant relationships to disclose
R. Pirker
No relevant relationships to disclose
H. H. Popper
No relevant relationships to disclose
X. Wang
Stock Ownership - On-Q-ity
Research Funding - On-Q-ity
Y. Chen
Stock Ownership - On-Q-ity
Research Funding - On-Q-ity
S. Quan
Stock Ownership - On-Q-ity
Research Funding - On-Q-ity
M. Filipits
No relevant relationships to disclose
L. Alaparthi
Stock Ownership - On-Q-ity
Research Funding - On-Q-ity
J. Kutok
Consultant or Advisory Role - On-Q-ity
Stock Ownership - On-Q-ity
D. T. Weaver
Consultant or Advisory Role - On-Q-ity
Stock Ownership - On-Q-ity
Research Funding - On-Q-ity
M. Al-Adhami
Research Funding - On-Q-ity
F. Andre
No relevant relationships to disclose
T. Le Chevalier
No relevant relationships to disclose
B. E. Ward
Stock Ownership - On-Q-ity
Research Funding - On-Q-ity
J. Soria
No relevant relationships to disclose